Astellas Submits New Drug Application for Enfortumab Vedotin in Japan

Corporate Breaking News

Home : Astellas Submits New Drug Application for Enfortumab Vedotin in Japan

Mar 11 2021	Astellas Submits New Drug Application for Enfortumab Vedotin in Japan
TOKYO, March 11, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for enfortumab vedotin for the treatment of...


Source:https://www.prnewswire.com:443/news-releases/astellas-submits-new-drug-application-for-enfortumab-vedotin-in-japan-301245252.html

Related News
» Kimera Labs Announces New Standard Measurement For Exosome Potency, Characterization » Trump insists 'something bad happened' in Ga. in call with election investigator: WSJ